• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

    11/14/24 7:30:00 AM ET
    $TRML
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TRML alert in real time by email

    NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist serving as Executive Director of CPC Clinical Research and Professor of Medicine and William R. Hiatt Endowed Chair in Cardiovascular Research at the University of Colorado Anschutz. Dr. Bonaca is also a member of Tourmaline's Cardiovascular Scientific Advisory Board.

    Tourmaline's Investor Day will feature insights and updates around the company's plans to further develop pacibekitug, highlighting the company's vision towards developing transformative therapies with the potential to address significant unmet needs.

    To register for Tourmaline's Investor Day, please click here or visit the "Events and Presentations" section of Tourmaline's website at https://ir.tourmalinebio.com/events-presentations/events.

    A replay will be archived on Tourmaline's website following the event.

    About Tourmaline Bio

    Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.

    About Pacibekitug

    Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration.

    Cautionary Note Regarding Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as "believe," "designed to," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on Tourmaline's current beliefs and expectations. These forward-looking statements include expectations regarding the Company's plans to further develop pacibekitug; the therapeutic potential of pacibekitug; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline's current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline's current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline's current or future product candidates; the risk that Tourmaline's current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline's estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline's business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") on November 7, 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Media Contact

    Scient PR

    Sarah Mishek

    [email protected]

    Investor Contact

    Meru Advisors

    Lee M. Stern

    [email protected]



    Primary Logo

    Get the next $TRML alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRML

    DatePrice TargetRatingAnalyst
    4/23/2025$70.00Buy
    Chardan Capital Markets
    3/6/2025$42.00Outperform
    Wedbush
    12/6/2024$50.00Outperform
    BMO Capital Markets
    11/11/2024$48.00 → $49.00Buy
    H.C. Wainwright
    12/15/2023$41.00Buy
    Jefferies
    12/4/2023$48.00Buy
    H.C. Wainwright
    11/17/2023$43.00Buy
    Truist
    10/31/2023$50.00Buy
    Guggenheim
    More analyst ratings

    $TRML
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Kulkarni Sandeep Chidambar

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      2/4/25 4:19:06 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Robinson Ryan F.

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:34 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CBO, GC and Secretary Middlekauff W Bradford

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:21 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    SEC Filings

    See more
    • Tourmaline Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/20/25 9:02:35 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tourmaline Bio Inc.

      SCHEDULE 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      5/15/25 4:22:00 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tourmaline Bio Inc.

      10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/2/25 8:12:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Financials

    Live finance-specific insights

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Tourmaline with a new price target

      Chardan Capital Markets initiated coverage of Tourmaline with a rating of Buy and set a new price target of $70.00

      4/23/25 8:18:16 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Tourmaline with a new price target

      Wedbush initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $42.00

      3/6/25 7:32:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Tourmaline with a new price target

      BMO Capital Markets initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $50.00

      12/6/24 8:19:37 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TRML
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TRML
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO Kulkarni Sandeep Chidambar bought $26,418 worth of shares (1,779 units at $14.85) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/22/24 4:22:14 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO Kulkarni Sandeep Chidambar bought $71,998 worth of shares (5,221 units at $13.79) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/20/24 6:09:47 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:46:12 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:05:20 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 4:32:01 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Leadership Updates

    Live Leadership Updates

    See more
    • Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). "We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of card

      1/10/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

      Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa

      4/2/24 7:00:00 AM ET
      $AVTX
      $TRML
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

      NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines

      12/14/23 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care